Conversion surgery for gastric cancer with limited peritoneal carcinomatosis
- 23 April 2024
- journal article
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (4)
Abstract
Conversion surgery for disseminated gastric cancer is attracting increasing attention as a new therapeutic strategy. A number of European and Asian studies on this topic have presented data on the advantage of performing cytoreductive surgery in a limited group of patients. Objective. To evaluate the safety and efficacy of conversion surgery for gastric cancer with limited peritoneal carcinomatosis. Material and methods. In the period from 2015 to 2022, 45 cytoreductive surgical interventions in patients with limited peritoneal carcinomatosis (PCI ≤7) in gastric cancer were performed in National Medical Radiology Research Center. Results. After preoperative drug treatment, 24 cases showed complete regression of carcinomatosis foci confirmed histologically and cytologically, while the remaining cases achieved partial response or stabilization. Surgical intervention was supplemented with hyperthermic intraoperative intra-abdominal chemotherapy or sessions of intra-abdominal aerosol chemotherapy. The extent of cytoreduction was considered as R0/CC-0 in 38 (84%) of 45 patients. Median overall survival was 24.1 months, with overall one- and two-year survival rates of 84.4 and 52%, respectively. Conclusion. Analysis of the results of conversion surgery for gastric cancer with limited peritoneal carcinomatosis has demonstrated the safety and efficacy of this approach with careful selection of patients. Further recruitment and analysis of the accumulated experience will make it possible to clarify the criteria for selecting patients for conversion surgery, as well as the optimal regimens of perioperative drug treatment.Keywords
This publication has 16 references indexed in Scilit:
- Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohortGastric Cancer, 2021
- Peritoneal metastasis in gastric cancer: results from the German databaseGastric Cancer, 2019
- Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction CancerJAMA Oncology, 2017
- The 30-year experience—A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancerEuropean Journal of Cancer, 2017
- Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findingsGastric Cancer, 2016
- Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trialThe Lancet Oncology, 2016
- Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: A systematic review of survival, mortality, and morbidityJournal of Surgical Oncology, 2011
- Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancerBritish Journal of Surgery, 2000
- Peritoneal-plasma barrier1996